Specifying Drug Resonance Chemotherapy: A Review

Abstract

Drug Resonance Chemotherapy (DRC) is an emerging therapeutic approach designed to enhance the precision and efficacy of cancer treatment by leveraging molecular resonance phenomena. Unlike conventional chemotherapy, which often results in systemic toxicity and multidrug resistance due to its non-specific action, DRC proposes a targeted mechanism wherein chemotherapeutic agents are modulated to interact with cancer cells at specific vibrational frequencies. This method theoretically improves drug-cell binding and reduces off-target effects. The review explores the foundational challenges in cancer therapy, particularly drug resistance caused by genetic mutations, epigenetic changes, efflux pumps, and phenotypic adaptations. DRC incorporates elements of nanotechnology, quantum chemistry, and biophysics to enhance drug delivery, increase bioavailability, and allow for controlled release at tumor sites. The manuscript discusses potential applications of DRC in malignancies such as breast, lung, leukemia, and glioblastoma; however, it notes that empirical evidence remains limited and primarily theoretical. While some early-stage studies and related technologies, like focused ultrasound and nanocarriers, suggest a promising future for resonance-based therapies, the clinical translation of DRC is still in its infancy. Challenges such as high implementation costs, technical complexity, and lack of regulatory clarity also hinder immediate adoption. Nevertheless, DRC represents a potentially transformative direction in oncology by aligning therapeutic specificity with personalized medicine. The review underscores the need for further experimental validation, mechanistic clarification, and clinical trials to establish DRC as a viable alternative or adjunct to traditional chemotherapy strategies.